MetaCap

Foghorn Therapeutics (FHTX) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Foghorn Therapeutics (FHTX) has outperformed Spruce Biosciences (SPRB) over the past year, losing 62.8% versus a loss of 63.8%. Over five years, FHTX leads with a -87.4% price change compared with -99.8% for SPRB. Spruce Biosciences is the larger company by market cap ($109.2 million vs $103.1 million), about 1.1 times the size, while Foghorn Therapeutics is growing revenue faster (+36.8% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FHTX-62.77%SPRB-63.81%
+59%-5%-70%
Nov 21, 20251 yearNov 20, 2026
FHTX-87.43%SPRB-99.77%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FHTX versus SPRB key metrics
MetricFHTXSPRB
Share price$1.72$38.00
Market cap$103.14M$109.21M
1-day change-3.37%-6.15%
YTD return-68.15%-56.38%
1-year return-62.77%-63.81%
5-year return-87.36%-99.75%
P/E ratio (TTM)19.11—
Forward P/E—11.79
EPS (TTM)$0.09$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$30.91M$0
Revenue growth (YoY)+36.75%-100.00%
Net income (latest FY)$-74.28M$-38.97M
Operating margin-279.49%—
Net margin-240.33%—
52-week high$7.61$111.00
52-week low$1.66$38.00
Distance from 52-week high-77.40%-65.77%
Analyst consensusbuystrong_buy
Avg. price target upside+142.44%+288.00%
Average volume843.73K89.33K
Shares outstanding59.96M2.87M
Employees10625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Foghorn Therapeutics grew revenue faster in its latest fiscal year (+36.75% vs -100.00%).

About Foghorn Therapeutics

FHTX stock →

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

FHTX vs SPRB FAQ

Which is bigger, Foghorn Therapeutics or Spruce Biosciences?

Spruce Biosciences (SPRB) is larger, with a market capitalization of $109.21M compared with $103.14M for Foghorn Therapeutics (FHTX).

Which stock has performed better over the past year, FHTX or SPRB?

FHTX returned -62.77% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.

Are Foghorn Therapeutics and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons